vtioВестник трансплантологии и искусственных органовRussian Journal of Transplantology and Artificial Organs1995-1191Academician V.I.Shumakov National Medical Research Center of Transplantology and Artificial Organs", Ministry of Health of the Russian Federation10.15825/1995-1191-2012-2-63-71vtio-165Research ArticleКлинические наблюденияClinical CasesУСПЕШНАЯ ABO-НЕСОВМЕСТИМАЯ ТРАНСПЛАНТАЦИЯ ПОЧКИ ОТ ЖИВОГО РОДСТВЕННОГО ДОНОРА ПАЦИЕНТУ ВЫСОКОГО ИММУНОЛОГИЧЕСКОГО РИСКАSUCCESSFUL ABO-INCOMPATIBLE KIDNEY TRANSPLANTATION FROM LIVING-RELATED DONOR IN HIGH-SENSITIZED PATIENTСушковА. И.SushkovA. I.БоровковаН. В.BorovkovaN. V.ДоронинаН. В.DoroninaN. V.МойсюкЯ. Г.ФГБУ «ФНЦ трансплантологии и искусственных органов им. академика В.И. Шумакова» Минздравсоцразвития России, г. МоскваAcademician V.I. Shumakov Federal Research Center of Transplantology and Artificial Organs, MoscowНаучно-исследовательский институт скорой помощи им. Н.В. Склифосовского, г. МоскваN.V. Sklifosovsky Research Institute of Emergency Care, Moscow201228052014142ВЕСТНИК ТРАНСПЛАНТОЛОГИИ И ИСКУССТВЕННЫХ ОРГАНОВ том XIV No 2–20126371Copyright © Сушков А.И., Боровкова Н.В., Доронина Н.В., Мойсюк Я.Г., 20122012Сушков А.И., Боровкова Н.В., Доронина Н.В., Мойсюк Я.Г.Sushkov A.I., Borovkova N.V., Doronina N.V., Мойсюк Я.Г.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.transpl.ru/vtio/article/view/165

В статье приводится описание случая ABO-несовместимой трансплантации почки пациенту с экстремаль- но высоким исходным титром анти-B IgM (1:1024), IgG (1:512) и высоким уровнем предсуществующих анти-HLA антител (60%), трансплантацией почки от трупного донора в анамнезе. Основное внимание уделено вопросам иммунологического мониторинга в течение предоперационного кондиционирования и в посттрансплантационном периоде. 

This case report describes a patient initially found to have an extremely high anti-B IgM (1:1024) and IgG (1:512) titres.Additionally, patient had previous diseased donor kidney transplantation and high level of anti-HLA panel- reactive antibodies (60%). We focused on immunological monitoring during the pretransplant conditioning and posttransplant period. 

трансплантация почкинесовместимость по группе кровианти-HLA антителаkidney transplantationblood group incompatibilityanti-HLA antibodiesReferencesOrgan Donation and Transplantation Activities 2010. 2011; Availablefrom: http://www.transplant-observatory.org/Data%20Reports/Basic%20slides%202010.pdf.Organ Donation and Transplantation Activities 2010. 2011; Availablefrom: http://www.transplant-observatory.org/Data%20Reports/Basic%20slides%202010.pdf.Бикбов Б.Т., Томилина Н.А. Состояние заместительной терапии больных с хронической почечной недостаточностью в Российской Федерации в 1998–2009 гг. // Нефрология и диализ. 2011. Т. 13 (3). С. 150–264.Бикбов Б.Т., Томилина Н.А. Состояние заместительной терапии больных с хронической почечной недостаточностью в Российской Федерации в 1998–2009 гг. // Нефрология и диализ. 2011. Т. 13 (3). С. 150–264.Мойсюк Я.Г., Сушков А.И., Пулькова Н.В. и др. Пер-вый отечественный опыт применения иммуноадсорбции при ABO-несовместимой трансплантации почки от живого родственного донора // Вестник трансплантологии и искусственных оргнов. 2011. Т. XIII, No 4. С. 6–18.Мойсюк Я.Г., Сушков А.И., Пулькова Н.В. и др. Пер-вый отечественный опыт применения иммуноадсорбции при ABO-несовместимой трансплантации почки от живого родственного донора // Вестник трансплантологии и искусственных оргнов. 2011. Т. XIII, No 4. С. 6–18.Шаршаткин А.В. Клинические и хирургические аспекты трансплантации почки от живого родствен- ного донора: Дис. ... докт. мед. наук. 2009. Москва.Шаршаткин А.В. Клинические и хирургические аспекты трансплантации почки от живого родствен- ного донора: Дис. ... докт. мед. наук. 2009. Москва.Akalin E., Pascual M. Sensitization after kidney trans- plantation // Clin. J. Am. Soc. Nephrol. 2006. Vol. 1 (3). P. 433–440.Akalin E., Pascual M. Sensitization after kidney trans- plantation // Clin. J. Am. Soc. Nephrol. 2006. Vol. 1 (3). P. 433–440.Alexandre G.P, et al. Human ABO-incompatible living donor renal homografts // Neth. J. Med. 1985. Vol. 28 (6). P. 231–234.Alexandre G.P, et al. Human ABO-incompatible living donor renal homografts // Neth. J. Med. 1985. Vol. 28 (6). P. 231–234.Breimer M.E. et al. Blood group A and B antigen expres- sion in human kidneys correlated to A1/A2/B, Lewis, and secretor status // Transplantation. 2006. Vol. 82 (4). P. 479–485.Breimer M.E. et al. Blood group A and B antigen expres- sion in human kidneys correlated to A1/A2/B, Lewis, and secretor status // Transplantation. 2006. Vol. 82 (4). P. 479–485.Crew R.J., Ratner L.E. ABO-incompatible kidney trans- plantation: current practice and the decade ahead // Curr. Opin Organ Transplant. 2010. Vol. 15 (4). P. 526–530.Crew R.J., Ratner L.E. ABO-incompatible kidney trans- plantation: current practice and the decade ahead // Curr. Opin Organ Transplant. 2010. Vol. 15 (4). P. 526–530.Delikouras A., Dorling A. Transplant accommodation // Am. J. Transplant. 2003. Vol. 3 (8). P. 917–918.Delikouras A., Dorling A. Transplant accommodation // Am. J. Transplant. 2003. Vol. 3 (8). P. 917–918.Gloor J.M. et al. A Comparison of splenectomy versus intensive posttransplant antidonor blood group antibody monitoring without splenectomy in ABO-incompatible kidney transplantation // Transplantation. 2005. Vol. 80 (11). P. 1572–1577.Gloor J.M. et al. A Comparison of splenectomy versus intensive posttransplant antidonor blood group antibody monitoring without splenectomy in ABO-incompatible kidney transplantation // Transplantation. 2005. Vol. 80 (11). P. 1572–1577.Haidinger M. et al. Vienna experience of ABO-incom- patible living-donor kidney transplantation // Wien. Klin. Wochenschr. 2009. Vol. 121 (7–8). P. 247–255.Haidinger M. et al. Vienna experience of ABO-incom- patible living-donor kidney transplantation // Wien. Klin. Wochenschr. 2009. Vol. 121 (7–8). P. 247–255.Hourmant M. et al. Frequency and clinical implications of development of donor-specific and non-donor-specific HLA antibodies after kidney transplantation // J. Am. Soc. Nephrol. 2005. Vol. 16 (9). P. 2804–2812.Hourmant M. et al. Frequency and clinical implications of development of donor-specific and non-donor-specific HLA antibodies after kidney transplantation // J. Am. Soc. Nephrol. 2005. Vol. 16 (9). P. 2804–2812.Ichimaru N., Takahara S. Japan’s experience with living- donor kidney transplantation across ABO barriers // Nat. Clin. Pract. Nephrol. 2008. Vol. 4 (12). P. 682–692.Ichimaru N., Takahara S. Japan’s experience with living- donor kidney transplantation across ABO barriers // Nat. Clin. Pract. Nephrol. 2008. Vol. 4 (12). P. 682–692.Kumlien G. et al. Clinical experience with a new aphere- sis filter that specifically depletes ABO blood group antibodies // Transfusion. 2006. Vol. 46 (9). P. 1568–1575.Kumlien G. et al. Clinical experience with a new aphere- sis filter that specifically depletes ABO blood group antibodies // Transfusion. 2006. Vol. 46 (9). P. 1568–1575.Lynch R.J., Platt J.L. Accommodation in renal trans- plantation: unanswered questions // Curr. Opin. Organ. Transplant. 2010. Vol. 15 (4). P. 481–485.Lynch R.J., Platt J.L. Accommodation in renal trans- plantation: unanswered questions // Curr. Opin. Organ. Transplant. 2010. Vol. 15 (4). P. 481–485.Oettl T. et al. ABO blood group-incompatible living do- nor kidney transplantation: a prospective, single-centre analysis including serial protocol biopsies // Nephrol. Dial. Transplant. 2009. Vol. 24 (1). P. 298–303.Oettl T. et al. ABO blood group-incompatible living do- nor kidney transplantation: a prospective, single-centre analysis including serial protocol biopsies // Nephrol. Dial. Transplant. 2009. Vol. 24 (1). P. 298–303.Racusen L.C. et al. Antibody-mediated rejection crite- ria – an addition to the Banff 97 classification of renal allograft rejection // Am. J. Transplant. 2003. Vol. 3 (6). P. 708–714.Racusen L.C. et al. Antibody-mediated rejection crite- ria – an addition to the Banff 97 classification of renal allograft rejection // Am. J. Transplant. 2003. Vol. 3 (6). P. 708–714.Sonnenday C.J. et al. Plasmapheresis, CMV hyperim-Sonnenday C.J. et al. Plasmapheresis, CMV hyperim-mune globulin, and anti-CD20 allow ABO-incompatible renal transplantation without splenectomy // Am. J. Transplant. 2004. Vol. 4 (8). P. 1315–1322.mune globulin, and anti-CD20 allow ABO-incompatible renal transplantation without splenectomy // Am. J. Transplant. 2004. Vol. 4 (8). P. 1315–1322.Takahashi K. et al. Excellent long-term outcome of ABO-incompatible living donor kidney transplantation in Japan // Am. J. Transplant. 2004. Vol. 4 (7). P. 1089– 1096.Takahashi K. et al. Excellent long-term outcome of ABO-incompatible living donor kidney transplantation in Japan // Am. J. Transplant. 2004. Vol. 4 (7). P. 1089– 1096.Tanabe K. et al. Long-term results of ABO-incompatible living kidney transplantation: a single-center experi- ence // Transplantation. 1998. Vol. 65 (2). P. 224–228Tanabe K. et al. Long-term results of ABO-incompatible living kidney transplantation: a single-center experi- ence // Transplantation. 1998. Vol. 65 (2). P. 224–228Tyden G. et al. Implementation of a Protocol for ABO- incompatible kidney transplantation-a three-center expe- rience with 60 consecutive transplantations // Transplan- tation. 2007. Vol. 83 (9). P. 1153–1155.Tyden G. et al. Implementation of a Protocol for ABO- incompatible kidney transplantation-a three-center expe- rience with 60 consecutive transplantations // Transplan- tation. 2007. Vol. 83 (9). P. 1153–1155.Tyden G. et al. ABO-incompatible kidney transplanta- tions without splenectomy, using antigen-specific immu- noadsorption and rituximab // Am. J. Transplant. 2005. Vol. 5 (1). P. 145–148.Tyden G. et al. ABO-incompatible kidney transplanta- tions without splenectomy, using antigen-specific immu- noadsorption and rituximab // Am. J. Transplant. 2005. Vol. 5 (1). P. 145–148.Ushigome H. et al. Findings of graft biopsy specimens within 90 days after ABO blood group incompatible li- ving donor kidney transplantation compared with ABO- identical and non-identical transplantation // Clin. Trans- plant. 2010. Vol. 24. Suppl 22. P. 16–21.Ushigome H. et al. Findings of graft biopsy specimens within 90 days after ABO blood group incompatible li- ving donor kidney transplantation compared with ABO- identical and non-identical transplantation // Clin. Trans- plant. 2010. Vol. 24. Suppl 22. P. 16–21.Wilpert J. et al. On-demand strategy as an alternative to conventionally scheduled post-transplant immunoadsorp- tions after ABO-incompatible kidney transplantation // Nephrol. Dial. Transplant. 2007. Vol. 22 (10). P. 3048–3051.Wilpert J. et al. On-demand strategy as an alternative to conventionally scheduled post-transplant immunoadsorp- tions after ABO-incompatible kidney transplantation // Nephrol. Dial. Transplant. 2007. Vol. 22 (10). P. 3048–3051.Wilpert J. et al. ABO-incompatible kidney transplan- tation-proposal of an intensified apheresis strategy for patients with high initial isoagglutinine titers // J. Clin. Apher. 2007. Vol. 22 (6). P. 314–322.Wilpert J. et al. ABO-incompatible kidney transplan- tation-proposal of an intensified apheresis strategy for patients with high initial isoagglutinine titers // J. Clin. Apher. 2007. Vol. 22 (6). P. 314–322.Zachary A.A., Leffell M.S. Barriers to successful trans- plantation of the sensitized patient // Expert. Rev. Clin. Immunol. 2010. Vol. 6 (3). P. 449–460.Zachary A.A., Leffell M.S. Barriers to successful trans- plantation of the sensitized patient // Expert. Rev. Clin. Immunol. 2010. Vol. 6 (3). P. 449–460.

The authors declare that there are no conflicts of interest present.